DiagonalLogo_DarkColor.png
Diagonal Therapeutics Initiates Natural History Study of Adults Living with Hereditary Hemorrhagic Telangiectasia (HHT), a Rare Bleeding Disorder with No Approved Treatments
March 04, 2025 07:07 ET | DIAGONAL THERAPEUTICS, INC
Diagonal Therapeutics today announced the initiation of a natural history study for HHT in partnership with patient advocacy group Cure HHT.
DiagonalLogo_DarkColor.png
Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT)
December 03, 2024 07:00 ET | DIAGONAL THERAPEUTICS, INC
Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT)
DiagonalLogo_DarkColor.png
Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference
October 08, 2024 07:00 ET | DIAGONAL THERAPEUTICS, INC
Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference
DiagonalLogo_DarkColor.png
Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases
April 03, 2024 06:00 ET | DIAGONAL THERAPEUTICS, INC
Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies